Simpson Thacher is representing JPMorgan Chase Bank, N.A. in connection with $1.75 billion committed financing for Bausch + Lomb Corporation (NYSE: BLCO) (“Bausch + Lomb”) in connection with Bausch + Lomb’s announced acquisition of XIIDRA®.
Bausch + Lomb is a leading global eye health company with a comprehensive portfolio of contact lenses, lens care products, eye care products, ophthalmic pharmaceuticals, over-the-counter products and ophthalmic surgical devices and instruments. XIIDRA®, which is currently held by Novartis, is a non-steroid eye drop specifically approved to treat the signs and symptoms of dry eye disease (DED) focusing on inflammation associated with dry eye.
The Simpson Thacher team includes Dan Kay, Patrick Wolff, Jule Walsh and Matthew Elkwood (Banking & Credit); John C. Ericson, Ignacio Perez and Courtney Kobren (Capital Markets); Vanessa Burrows and Nawa Lodin (Healthcare); Jessica Cohen and Rachelle Broida (Intellectual Property); Malik Ladhani and Cedric Karaoglan (Mergers & Acquisitions); Michael Mann (Tax); and Ryan Stott (Executive Compensation & Employee Benefits).